Gene Chang, MD
Interventional Cardiology · Philadelphia, PANPI 1174554851
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,840 of the $7,786 with a category attached, or 62.2%. 19 manufacturers reported payments, led by Abbott at 35.9% of the total. 2025 is the largest year on record at $3,003, 7.7 times the $390 reported in 2019.
Across 138 payments — averaging $56.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Edwards Lifesciences$2K
- W. L. Gore & Associates, Inc.$951
- Abiomed$710
- Medtronic$270
- Cardiac Dimensions, Inc.$258
- plus $1K from 13 others
Across 54 payments — averaging $3868.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$122K
- Abbott$85K
- Atricure, Inc.$2K
What the payments were for
- Travel & lodging$2,94638%
- Food & beverage$4,84062%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 26 | $2,796 |
| Edwards Lifesciences | 12 | $1,694 |
| W. L. Gore & Associates, Inc. | 34 | $951 |
| Abiomed | 15 | $710 |
| Medtronic(2 entities) | 17 | $270 |
| Cardiac Dimensions, Inc. | 1 | $258 |
| Acist Medical Systems, Inc. | 2 | $253 |
| Shockwave Medical, Inc | 5 | $180 |
| Siemens Medical Solutions USA, Inc. | 3 | $130 |
| Boston Scientific | 4 | $128 |
| Cardiva Medical, Inc. | 4 | $107 |
| Amgen | 3 | $69 |
| Cook Medical LLC | 4 | $59 |
| Teleflex LLC | 2 | $44 |
| Philips North America LLC | 2 | $43 |
| Cathworks, Inc. | 1 | $43 |
| Impulse Dynamics (USA) Inc. | 1 | $28 |
| AstraZeneca | 1 | $11 |
| Cardiovascular Systems Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,786 in reported general payments places this provider in the 55th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 34 | $33,091 |
| XareltoRivaroxaban | 28 | $25,848 |
| EntrestoSacubitril/Valsartan | 24 | $19,533 |
| Repatha SureclickEvolocumab | 20 | $11,050 |
| FarxigaDapagliflozin Propanediol | 20 | $10,959 |
| CozaarLosartan Potassium | 13 | $2,223 |
| Atorvastatin Calcium | 97 | $1,648 |
| Metoprolol Succinate | 85 | $1,621 |
| Rosuvastatin Calcium | 62 | $1,572 |
| ClopidogrelClopidogrel Bisulfate | 68 | $714 |
| Pantoprazole Sodium | 19 | $606 |
| Amlodipine Besylate | 65 | $572 |
| Ramipril | 24 | $450 |
| Valsartan | 15 | $441 |
| Carvedilol | 41 | $374 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $11 | $10,95920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Philadelphia
- Jon GeorgePhiladelphia$637K
- Sanjog KalraPhiladelphia$444K
- Taisei KobayashiPhiladelphia$384K
- Howard HerrmannPhiladelphia$259K
- Jay GiriPhiladelphia$157K
- Paul FiorilliPhiladelphia$104K
- Nicholas RuggieroPhiladelphia$74K
- Craig FrankilPhiladelphia$59K
- Michael BodePhiladelphia$58K
- Oleg VishnevskyPhiladelphia$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.